365 related articles for article (PubMed ID: 33584555)
1. The Therapeutic Efficacy of Curcumin vs. Metformin in Modulating the Gut Microbiota in NAFLD Rats: A Comparative Study.
Li R; Yao Y; Gao P; Bu S
Front Microbiol; 2020; 11():555293. PubMed ID: 33584555
[TBL] [Abstract][Full Text] [Related]
2. Curcumin alleviates high-fat diet-induced hepatic steatosis and obesity in association with modulation of gut microbiota in mice.
Li S; You J; Wang Z; Liu Y; Wang B; Du M; Zou T
Food Res Int; 2021 May; 143():110270. PubMed ID: 33992371
[TBL] [Abstract][Full Text] [Related]
3. Modulation of gut microbiota contributes to curcumin-mediated attenuation of hepatic steatosis in rats.
Feng W; Wang H; Zhang P; Gao C; Tao J; Ge Z; Zhu D; Bi Y
Biochim Biophys Acta Gen Subj; 2017 Jul; 1861(7):1801-1812. PubMed ID: 28341485
[TBL] [Abstract][Full Text] [Related]
4. Targeting the gut microbiota with resveratrol: a demonstration of novel evidence for the management of hepatic steatosis.
Wang P; Wang J; Li D; Ke W; Chen F; Hu X
J Nutr Biochem; 2020 Jul; 81():108363. PubMed ID: 32388250
[TBL] [Abstract][Full Text] [Related]
5. Structural modulation of gut microbiota during alleviation of non-alcoholic fatty liver disease with Gynostemma pentaphyllum in rats.
Shen SH; Zhong TY; Peng C; Fang J; Lv B
BMC Complement Med Ther; 2020 Feb; 20(1):34. PubMed ID: 32024509
[TBL] [Abstract][Full Text] [Related]
6. Modulation of the Gut Microbiota in Rats by Hugan Qingzhi Tablets during the Treatment of High-Fat-Diet-Induced Nonalcoholic Fatty Liver Disease.
Tang W; Yao X; Xia F; Yang M; Chen Z; Zhou B; Liu Q
Oxid Med Cell Longev; 2018; 2018():7261619. PubMed ID: 30671174
[TBL] [Abstract][Full Text] [Related]
7. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
[TBL] [Abstract][Full Text] [Related]
8. Effects of shenling baizhu powder herbal formula on intestinal microbiota in high-fat diet-induced NAFLD rats.
Zhang Y; Tang K; Deng Y; Chen R; Liang S; Xie H; He Y; Chen Y; Yang Q
Biomed Pharmacother; 2018 Jun; 102():1025-1036. PubMed ID: 29710519
[TBL] [Abstract][Full Text] [Related]
9. Liraglutide Attenuates Nonalcoholic Fatty Liver Disease by Modulating Gut Microbiota in Rats Administered a High-Fat Diet.
Zhang N; Tao J; Gao L; Bi Y; Li P; Wang H; Zhu D; Feng W
Biomed Res Int; 2020; 2020():2947549. PubMed ID: 32149099
[TBL] [Abstract][Full Text] [Related]
10. Diammonium Glycyrrhizinate Protects against Nonalcoholic Fatty Liver Disease in Mice through Modulation of Gut Microbiota and Restoration of Intestinal Barrier.
Li Y; Liu T; Yan C; Xie R; Guo Z; Wang S; Zhang Y; Li Z; Wang B; Cao H
Mol Pharm; 2018 Sep; 15(9):3860-3870. PubMed ID: 30036479
[TBL] [Abstract][Full Text] [Related]
11. Changes of gut microbiota during silybin-mediated treatment of high-fat diet-induced non-alcoholic fatty liver disease in mice.
Li X; Wang Y; Xing Y; Xing R; Liu Y; Xu Y
Hepatol Res; 2020 Jan; 50(1):5-14. PubMed ID: 31661720
[TBL] [Abstract][Full Text] [Related]
12. Beneficial effects of exercise on gut microbiota functionality and barrier integrity, and gut-liver crosstalk in an
Carbajo-Pescador S; Porras D; García-Mediavilla MV; Martínez-Flórez S; Juarez-Fernández M; Cuevas MJ; Mauriz JL; González-Gallego J; Nistal E; Sánchez-Campos S
Dis Model Mech; 2019 Apr; 12(5):. PubMed ID: 30971408
[TBL] [Abstract][Full Text] [Related]
13. Deletion of the PPARδ gene exacerbates high-fat diet-induced nonalcoholic fatty liver disease in mice through the gut-liver axis.
Wang YT; Wang FF; Li H; Xu JY; Lu XL; Wang Y
Cell Mol Biol (Noisy-le-grand); 2023 Oct; 69(10):121-128. PubMed ID: 37953575
[TBL] [Abstract][Full Text] [Related]
14. Tectorigenin ameliorated high-fat diet-induced nonalcoholic fatty liver disease through anti-inflammation and modulating gut microbiota in mice.
Duan R; Huang K; Guan X; Li S; Xia J; Shen M; Sun Z; Yu Z
Food Chem Toxicol; 2022 Jun; 164():112948. PubMed ID: 35390440
[TBL] [Abstract][Full Text] [Related]
15. A combination of quercetin and resveratrol reduces obesity in high-fat diet-fed rats by modulation of gut microbiota.
Zhao L; Zhang Q; Ma W; Tian F; Shen H; Zhou M
Food Funct; 2017 Dec; 8(12):4644-4656. PubMed ID: 29152632
[TBL] [Abstract][Full Text] [Related]
16. Inulin Exerts Beneficial Effects on Non-Alcoholic Fatty Liver Disease via Modulating gut Microbiome and Suppressing the Lipopolysaccharide-Toll-Like Receptor 4-Mψ-Nuclear Factor-κB-Nod-Like Receptor Protein 3 Pathway via gut-Liver Axis in Mice.
Bao T; He F; Zhang X; Zhu L; Wang Z; Lu H; Wang T; Li Y; Yang S; Wang H
Front Pharmacol; 2020; 11():558525. PubMed ID: 33390939
[No Abstract] [Full Text] [Related]
17. Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease.
Wang W; Zhao J; Gui W; Sun D; Dai H; Xiao L; Chu H; Du F; Zhu Q; Schnabl B; Huang K; Yang L; Hou X
Br J Pharmacol; 2018 Feb; 175(3):469-484. PubMed ID: 29139555
[TBL] [Abstract][Full Text] [Related]
18. The combination of berberine and evodiamine ameliorates high-fat diet-induced non-alcoholic fatty liver disease associated with modulation of gut microbiota in rats.
Dai Y; Zhu W; Zhou J; Shen T
Braz J Med Biol Res; 2022; 55():e12096. PubMed ID: 35584453
[TBL] [Abstract][Full Text] [Related]
19. Lactobacillus plantarum NA136 ameliorates nonalcoholic fatty liver disease by modulating gut microbiota, improving intestinal barrier integrity, and attenuating inflammation.
Zhao Z; Chen L; Zhao Y; Wang C; Duan C; Yang G; Niu C; Li S
Appl Microbiol Biotechnol; 2020 Jun; 104(12):5273-5282. PubMed ID: 32335723
[TBL] [Abstract][Full Text] [Related]
20. Absence of the Caspases 1/11 Modulates Liver Global Lipid Profile and Gut Microbiota in High-Fat-Diet-Induced Obese Mice.
de Sant'Ana LP; Ribeiro DJS; Martins AMA; Dos Santos FN; Corrêa R; Almeida RDN; Eberlin MN; Maurice CF; Magalhães KG
Front Immunol; 2019; 10():2926. PubMed ID: 31998283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
